Drugs / HIV-1 C4-V3 Polyvalent Peptide Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001060 | ? → Jun 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 C4-V3 Polyvalent Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001060 ↗ |
| Known as | C4-V3 PV | “Eight patients received the C4-V3 PV immunogen emulsified in incomplete Freund's adjuvant in five intramuscular injections over 24 weeks” PMID 9708408 ↗ Jul 1998 |
| Modality | Peptide | “The immunogen comprised four peptides containing T-helper epitopes from the fourth constant region (C4) of gp120 of HIV-1MN, and T-helper, cytotoxic T-lymphocyte...” PMID 9708408 ↗ Jul 1998 |
| Route | Intramuscular | “Eight patients received the C4-V3 PV immunogen emulsified in incomplete Freund's adjuvant in five intramuscular injections over 24 weeks” PMID 9708408 ↗ Jul 1998 |